The biliary elimination of the selective beta-receptor blocking drug talinolol in man
- PMID: 2565889
The biliary elimination of the selective beta-receptor blocking drug talinolol in man
Abstract
The biliary elimination of the beta-1-receptor blocking agent talinolol was investigated after intravenous administration of 30 mg in 6 patients with a T-tube drain after cholecystectomy. Serum concentration decreased in a biexponential manner with a median terminal half-life time of 4.4 h (range: 3.0-6.2 h). In some patients a second peak of the serum level was found. Concentration-time curves in bile paralleled serum profiles. The bile:serum concentration ratio (b:s-ratio) ranged from 24 to 98. The biliary clearance amounted to 43 ml/h.kg (range: 13-212 ml/h.kg). The median of the amount of talinolol eliminated by bile was 2.8 mg (range: 1.1-7.4 mg). It is concluded that talinolol undergoes an enterohepatic circulation. However, the amount eliminated cannot provide a sufficient explanation for the second peak, observed in some patients.
Similar articles
-
On the pharmacokinetics of talinolol, a new beta 1-receptor blocking agent.Int J Clin Pharmacol Ther Toxicol. 1981 Sep;19(9):392-5. Int J Clin Pharmacol Ther Toxicol. 1981. PMID: 6117520
-
Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.Xenobiotica. 2009 Sep;39(9):694-9. doi: 10.1080/00498250903060077. Xenobiotica. 2009. PMID: 19555315 Clinical Trial.
-
Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.Clin Pharmacol Ther. 2007 May;81(5):669-78. doi: 10.1038/sj.clpt.6100191. Epub 2007 Mar 28. Clin Pharmacol Ther. 2007. PMID: 17392718 Clinical Trial.
-
Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.Clin Pharmacol Ther. 1999 Mar;65(3):283-90. doi: 10.1016/S0009-9236(99)70107-4. Clin Pharmacol Ther. 1999. PMID: 10096260 Clinical Trial.
-
[Correlation between pharmacokinetics and dynamics: explanation of clinical aspects exemplified by beta-receptor blockers].Verh Dtsch Ges Inn Med. 1991;97:338-42. Verh Dtsch Ges Inn Med. 1991. PMID: 1687299 Review. German. No abstract available.
Cited by
-
The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.Pharm Res. 2005 May;22(5):728-35. doi: 10.1007/s11095-005-2588-5. Epub 2005 May 17. Pharm Res. 2005. PMID: 15906167 Clinical Trial.
-
Interaction of talinolol and sulfasalazine in the human gastrointestinal tract.Eur J Clin Pharmacol. 1992;42(4):461-2. doi: 10.1007/BF00280137. Eur J Clin Pharmacol. 1992. PMID: 1355428
-
Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity - implications for mechanistic pharmacokinetics modeling.Sci Rep. 2019 Jul 19;9(1):10505. doi: 10.1038/s41598-019-46977-0. Sci Rep. 2019. PMID: 31324853 Free PMC article.
-
Multiple peaking phenomena in pharmacokinetic disposition.Clin Pharmacokinet. 2010 Jun;49(6):351-77. doi: 10.2165/11319320-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20481648 Review.
-
In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.Pharm Res. 2006 Aug;23(8):1712-20. doi: 10.1007/s11095-006-9020-7. Pharm Res. 2006. PMID: 16832615